<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703634</url>
  </required_header>
  <id_info>
    <org_study_id>Interventional</org_study_id>
    <nct_id>NCT04703634</nct_id>
  </id_info>
  <brief_title>The Effect of Ultrasound-guided Erector Spinae Block on Postoperative in Patients Undergoing Nephrectomy.</brief_title>
  <official_title>The Effect of Ultrasound-guided Erector Spinae Block on Postoperative Analgesic Consumption in Patients Undergoing Nephrectomy. Prospective Randomized Single-center Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Namik Kemal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Namik Kemal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the postoperative effect of erector spinae&#xD;
      block in patients undergoing nephrectomy that causes both visceral and somatic pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed and potential risks about the study, all patients have given written&#xD;
      consent will undergo 24 hours screening for the analgesic effect of erector spinae block&#xD;
      after nephrectomy. Patients meeting the criteria were randomly selected in double-blind&#xD;
      manner 1:1 ratio to erector spiane block or not.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Actual">May 17, 2021</completion_date>
  <primary_completion_date type="Actual">May 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>It is a single centre, randomized, prospective method comparison study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Scale (NRS)</measure>
    <time_frame>24 hours</time_frame>
    <description>Numerical Rating Scale (NRS) will be used for postoperative evaluation. NRS is a segmented digital version of the visual analog scale. Selecting an integer (0-10 integers) by a responder in (VAS). It is accepted as one dimensional-the measure of pain intensity in adults. The 11-point numerical scale ranges from &quot;0&quot; to &quot;10,&quot; representing a pain (&quot;no pain&quot;). 10 (&quot;as bad pain as you can imagine&quot;), or (&quot;the worst pain imaginable&quot;).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>Secondary outcome measures will be routine (paracetamol or tramadol PCA) or recovery. Analgesic use will be recorded within the first 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative nausea and vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>The severity of nausea and vomiting 4-point scale (none, mild, moderate, and severe). As will be recorded by the nurses in the ward.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Nephrectomy</condition>
  <arm_group>
    <arm_group_label>erector spinae group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All blocks will be done under general anesthesia. Using a 6-10 MHz linear ultrasound (Esaote my-lab 6, Italy). With the ultrasonography device of our clinic, the side of the nephrectomy surgery will be performed with the position of the nephrectomy, and the position (lateral decubitus) is given to the patient. The thoracic 10th vertebra will be found under ultrasound guidance. After the T12 transverse protrusion is seen by sliding 3 cm laterally from the midline, 30 ml of 0.25% Bupivacaine will be injected under the erector spinae muscle above it.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No block transaction will be applied to this group. Only postoperative analgesia methods will be used for this group as specified in the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>erector spinae block (ESP)</intervention_name>
    <description>Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra</description>
    <arm_group_label>erector spinae group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. To undergo partial or total nephrectomy surgery&#xD;
&#xD;
          2. To be in ASA I-II classification&#xD;
&#xD;
          3. To be between the ages of 18-65.&#xD;
&#xD;
          4. Not having problems that prevent erector spinae block application such as local&#xD;
             anesthetic drug allergy, infection at the injection site, and structural anomaly.&#xD;
&#xD;
          5. Being in good mental and psychological health&#xD;
&#xD;
          6. To accept to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Being in ASA III or IV class with a high risk of anesthesia&#xD;
&#xD;
          2. Being outside the age range of 18-65&#xD;
&#xD;
          3. Having problems such as local anesthetic drug allergy, infection at the injection&#xD;
             site, and structural anomaly prevents block application.&#xD;
&#xD;
          4. Not being mentally and psychologically healthy&#xD;
&#xD;
          5. Those who are allergic to the active substance, patients using antiepileptic drugs&#xD;
&#xD;
          6. Those with severe hepatic and renal failure&#xD;
&#xD;
          7. Those who have long-term use of nonsteroidal anti-inflammatory and opioid analgesic,&#xD;
&#xD;
          8. Those with diabetes and other neuropathic diseases&#xD;
&#xD;
          9. Patients who cannot use patient-controlled analgesia (PCA) device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayhan ŞAHİN</last_name>
    <role>Study Chair</role>
    <affiliation>Namık Kemal University Medicine Faculty</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Namık Kemal University</name>
      <address>
        <city>Tekirdağ</city>
        <state>Süleymanpaşa</state>
        <zip>59100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Namik Kemal University</investigator_affiliation>
    <investigator_full_name>Ayhan ŞAHİN</investigator_full_name>
    <investigator_title>Asistant Prof</investigator_title>
  </responsible_party>
  <keyword>erector spinae block</keyword>
  <keyword>nephrectomy</keyword>
  <keyword>ultrasound</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Participant data will be shared as much as the tasks described in the study. A meeting will be held at the end of the research, and the statistical data results will be shared. Dr. Ayhan Şahin is responsible.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>starting after 6 months publication</ipd_time_frame>
    <ipd_access_criteria>After publication, sharing will be made according to the journal criteria.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

